FDA's new Office of Post-Marketing Drug Assessment to track Phase IV studies.
This article was originally published in The Tan Sheet
Executive Summary
FDA OFFICE OF POST-MARKETING DRUG RISK ASSESSMENT (OPDRA) will track Phase IV studies of approved NDAs, Center for Drug Evaluation & Research Deputy Director for Review Management Murray Lumpkin, MD, says in a Dec. 23 memo to FDA employees. NDAed OTC products will fall under the new office's purview; monographed OTCs will not be affected by the change.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning